Kate Therapeutics Debuts With $51 Million Series A to Develop Next-Generation Genetic Medicines to Treat Muscle and Heart Diseases
Series A financing co-led by Westlake Village BioPartners and Versant Ventures
Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms
Initial pipeline addressing myotoni... Regenerative Medicine, Venture Capital Kate Therapeutics, gene therapy, X-linked myotubular myopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Centronuclear Myopathies | Gene Therapy | Genetics | Heart | Liver | Pharmaceuticals | Urology & Nephrology | Venture Capital